An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.

An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.

EOLO PHARMA today announced that it has dosed the first subjects in Phase 1 clinical trials of MVD1, designed to prevent and treat obesity and its cardiometabolic complications.

An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.

Carlos Escande lidera desde 2013 el Laboratorio de Patologías del Metabolismo y el Envejecimiento. Llegó al instituto luego de ser seleccionado con el último llamado internacional para jóvenes líderes que tenía un fondo por cinco años con el objetivo de entender los mecanismos de evolución de las patologías del metabolismo como obesidad, diabetes y enfermedades cardiovasculares.

EOLO PHARMA today announced that it has dosed the first subjects in Phase 1 clinical trials of MVD1, designed to prevent and treat obesity and its cardiometabolic complications.